Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for the treatment of Alzheimer's-related dementia
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Launching in 2022, its availability will be expanded to the global market
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Developed by the Sudha Gopalakrishnan Brain Centre, the publicly accessible ANCHOR atlas maps over 200 brainstem structures at cellular resolution, offering new possibilities for neuroscience research and clinical applications
Adya Anubhuti launches ADHD Copilot, an AI-powered platform designed to reduce stress and mental overload
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
